Skip to content

Akshita Goyal Assignments

Since co-founding Dasra in 1999, Deval has provided philanthropists with intelligent investment strategies resulting in over USD 58 million of capital being directed into the social sector in India. He incubated the Dasra Philanthropy Forum and the Dasra Philanthropy Week and has engaged over 3,000 philanthropists, multi-lateral agencies and corporate foundations that collectively drive the philanthropy agenda in India and internationally. He also initiated the Dasra Giving Circle – India’s largest collaborative giving platform, which combines in-depth research, funding and managerial support to non-profits to enable scale of 15-30x.

He has written articles for media publications such as Mint, Business India and Alliance Magazine and has been quoted in NDTV, Times of India, Economic Times, Hindustan Times and Mint. He has spoken at platforms such as the Global Philanthropy Forum, We the People-NDTV, The Outsider-Bloomberg TV, Unconvention-Forum, SOCAP. He was awarded the Forbes Philanthropy Award in the 'Crossover Leaders‘ category for 2014 for successfully transitioning from a thriving career in investment banking to work for the nonprofit sector.

Deval holds a Bachelor of Business Administration with a dual Honors degree in Business and Finance from the University of Texas, Austin, is a Cordes Fellow and a founding board member of Magic Bus and Villgro.

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807–4812.[PMC free article][PubMed]

2. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep. 2008;10:568–575.[PMC free article][PubMed]

3. Annese V, Andreoli A, Astegiano M, et al. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am J Gastroenterol. 2001;96:2939–2945.[PubMed]

4. Sachar DB. Crohn's disease: a family affair. Gastroenterology. 1996;111:813–815.[PubMed]

5. Orholm M, Binder V, Sørensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol. 2000;35:1075–1081.[PubMed]

6. Tysk C, Lindberg E, Järnerot G, Flodérus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut. 1988;29:990–996.[PMC free article][PubMed]

7. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–124.[PMC free article][PubMed]

8. Ahuja V, Tandon RK. Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol. 2012;31:294–296.[PubMed]

9. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134–147.[PubMed]

10. Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis. 2016;22:1954–1960.[PubMed]

11. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84–88.[PubMed]

12. Roma ES, Panayiotou J, Pachoula J, et al. Inflammatory bowel disease in children: the role of a positive family history. Eur J Gastroenterol Hepatol. 2010;22:710–715.[PubMed]

13. Ng SC, Zeng Z, Niewiadomski O, et al. Early course of inflammatory bowel disease in a population-based inception cohort study from 8 countries in Asia and Australia. Gastroenterology. 2016;150:86–95.e3.[PubMed]

14. Park JB, Yang SK, Byeon JS, et al. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis. 2006;12:1146–1151.[PubMed]

15. Kuwahara E, Asakura K, Nishiwaki Y, et al. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 2012;47:961–968.[PubMed]

16. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.[PubMed]

17. Makharia GK, Ramakrishna BS, Abraham P, et al. Survey of inflammatory bowel diseases in India. Indian J Gastroenterol. 2012;31:299–306.[PubMed]

18. Monsén U, Broström O, Nordenvall B, Sörstad J, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with ulcerative colitis. Scand J Gastroenterol. 1987;22:214–218.[PubMed]

19. Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut. 1993;34:517–524.[PMC free article][PubMed]

20. Roth MP, Petersen GM, McElree C, Vadheim CM, Panish JF, Rotter JI. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology. 1989;96:1016–1020.[PubMed]

21. Russel MG, Pastoor CJ, Janssen KM, et al. Familial aggregation of inflammatory bowel disease: a population-based study in South Limburg, the Netherlands: the South Limburg IBD Study Group. Scand J Gastroenterol Suppl. 1997;223:88–91.[PubMed]

22. Niriella MA, De Silva AP, Dayaratne AH, et al. Prevalence of inflammatory bowel disease in two districts of Sri Lanka: a hospital based survey. BMC Gastroenterol. 2010;10:32.[PMC free article][PubMed]

23. Chung SH, Park SJ, Lee HS, et al. Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea. World J Gastroenterol. 2014;20:17120–17126.[PMC free article][PubMed]

24. Hwang SW, Kwak MS, Kim WS, et al. Influence of a positive family history on the clinical course of inflammatory bowel disease. J Crohns Colitis. 2016;10:1024–1032.[PubMed]

25. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol. 2002;8:158–161.[PMC free article][PubMed]

26. Myung SJ, Yang SK, Jung HY, et al. HLA-DRB1*1502 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: a Korean study. Int J Colorectal Dis. 2002;17:233–237.[PubMed]

27. Futami S, Aoyama N, Honsako Y, et al. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig Dis Sci. 1995;40:814–818.[PubMed]

28. Yoshitake S, Kimura A, Okada M, Yao T, Sasazuki T. HLA class II alleles in Japanese patients with inflammatory bowel disease. Tissue Antigens. 1999;53(4 Pt 1):350–358.[PubMed]

29. Satsangi J, Welsh KI, Bunce M, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet. 1996;347:1212–1217.[PubMed]

30. Cottone M, Bunce M, Taylor CJ, Ting A, Jewell DP. Ulcerative colitis and HLA phenotype. Gut. 1985;26:952–954.[PMC free article][PubMed]

31. De La Concha EG, Fernandez-Arquero M, Santa-Cruz S, et al. Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC) Clin Exp Immunol. 1997;108:392–395.[PMC free article][PubMed]

32. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979–986.[PMC free article][PubMed]

33. Juyal G, Negi S, Sood A, et al. Genome-wide association scan in north Indians reveals three novel HLA-independent risk loci for ulcerative colitis. Gut. 2015;64:571–579.[PubMed]

34. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology. 2002;123:86–91.[PubMed]

35. Leong RW, Armuzzi A, Ahmad T, et al. NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther. 2003;17:1465–1470.[PubMed]

36. Croucher PJ, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet. 2003;11:6–16.[PubMed]

37. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599–603.[PubMed]

38. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606.[PubMed]

39. Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B IBSEN Study Group. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol. 2007;102:1955–1963.[PubMed]

40. Palli D, Saieva C, Trallori G, et al. A population-based study of familial clustering of inflammatory bowel disease in florence. Eur J Public Health. 1997;7:109–112.

41. Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut. 1996;38:738–741.[PMC free article][PubMed]

42. Andreu M, Márquez L, Domènech E, et al. Disease severity in familial cases of IBD. J Crohns Colitis. 2014;8:234–239.[PubMed]

43. Höweler CJ, Busch HF, Geraedts JP, Niermeijer MF, Staal A. Anticipation in myotonic dystrophy: fact or fiction? Brain. 1989;112(Pt 3):779–797.[PubMed]